Locations:
Search
Robust signal from observational study raises prospect of a long-sought medical therapy
Post hoc analysis of SURPASS-CVOT trial has implications for future cardiovascular outcome trials
Retrospective analysis finds lower mortality rates, fewer hospital visits among patients with Type 1 diabetes using GLP-1 Therapies
Data could help inform policy and patient-provider conversations
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Study shows significantly reduced risk of mortality and disease complications in patients receiving GLP-1 agonists
A reconcilable divorce
Observational evidence of neuroprotection with GLP-1 receptor agonists and SGLT-2 inhibitors
Study is first to show reduction in autoimmune disease with the common diabetes and obesity drugs
Surgical intervention linked to increased lifespan and reduced complications
Evidence mounts that these diabetes and obesity drugs may protect eyes, not endanger them
Advertisement
Advertisement